President Donald Trump signed an executive order on April 18, 2026 [1], to accelerate research and access to psychedelic drug treatments for mental health.
The move represents a shift in federal policy toward substances that have historically been strictly regulated. By streamlining the research process, the administration seeks to identify more effective therapeutic options for patients who do not respond to traditional psychiatric medications.
The order focuses on expanding the study of the therapeutic benefits of psychedelics for a variety of mental health conditions [2]. A primary objective of the initiative is to provide new treatment avenues for veterans struggling with trauma and other psychological injuries [3].
Among the substances highlighted for further investigation is ibogaine, a psychedelic compound that researchers are studying for its potential in treating addiction and depression [4]. The executive order urges federal agencies to reduce bureaucratic hurdles that have previously slowed clinical trials and academic studies on these compounds [4].
This policy change aims to expedite the path from laboratory research to clinical application. By increasing federal support for these studies, the administration intends to broaden the availability of these treatments across the U.S. healthcare system [2].
The directive comes as part of a broader effort to reform how the government approaches mental health crises. The administration said the goal is to integrate innovative science into standard care to improve patient outcomes [2].
“President Donald Trump signed an executive order on April 18, 2026, to accelerate research and access to psychedelic drug treatments.”
This executive order signals a pivot in U.S. drug policy, moving away from a purely punitive approach toward a medicalized framework for psychedelics. By specifically targeting veterans and mental health conditions, the administration is leveraging clinical research to address systemic gaps in the current healthcare infrastructure, potentially paving the way for the FDA to approve previously banned substances as prescription therapies.
